XML 43 R25.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Loss Per Share | 12 Months Ended
--- | ---
Dec. 31, 2024
Earnings Per Share [Abstract] |
Net Loss Per Share | Note 16 — Net Loss Per Share The Net loss per share basic and diluted for the respective periods indicated is as follows: Schedule of Net Loss Per Share Basic and Diluted
|  | 2024 |  |  | 2023 |
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Numerator |  |  |  |  |  |  |  |
Net loss |  | $ | (45,529 | ) |  | $ | (52,666 | )
Deemed dividend on Series A and Series A-1 Convertible Preferred Stock |  |  | (7,496 | ) |  |  | — |
Net loss attributable to Lucid Diagnostics Inc. common stockholders |  | $ | (53,025 | ) |  | $ | (52,666 | )
Denominator |  |  |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted |  |  | 50,515,773 |  |  |  | 41,756,129 |
Net loss per share (1) |  |  |  |  |  |  |  |
Net loss per share - basic and diluted |  | $ | (1.05 | ) |  | $ | (1.26 | )
(1) | - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.
Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all years presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
|  | 2024 |  |  | 2023 |
|  | December 31, |
|  | 2024 |  |  | 2023 |
Stock options |  |  | 8,646,758 |  |  |  | 5,504,383 |
Unvested restricted stock awards |  |  | 3,897,440 |  |  |  | 2,337,440 |
Preferred stock |  |  | 49,607,115 |  |  |  | 13,744,812 |
Total |  |  | 62,151,313 |  |  |  | 21,586,635 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration